Biopharma Insights - page 3

Unlocking the Full Potential of Precision Medicine: Why Companion Diagnostics Must Start at Discovery

Precision medicine has transformed the way we treat cancer, making it possible to match therapies to the molecular profile of each patient and revolutionize treatment approaches, leading to better outcomes. …

Continue ›››

From Electronic Noses to Agentic Drug Design: What Cancer AI Looks Like Now

Cancer AI has moved into some unusual territory. In one recent example, researchers at Linköping University reported that a 32-sensor electronic nose could distinguish ovarian cancer in blood plasma in …

Continue ›››

The €25B vs €219B Problem: Europe's Plan to Fix Biotech

Brussels is counting on new laws, sovereign AI, and billions in fresh capital to close the gap. The clock is ticking. Between 2015 and mid-2025, EU biotech startups attracted €25B …

Continue ›››

Cancer as a Data Problem: What AI Is Doing in Oncology

We track what has moved from promise to proximate execution, from AI-assisted candidate design with 2026 trial targets to agentic workflows that aim to handle multi-step oncology research tasks. Cancer …

Continue ›››

Tamarind Bio Raises $13.6M to Run 200+ AI and Simulation Models in a No-Code Platform for Bench Scientists

Tamarind Bio has secured $13.6 million in Series A financing led by Dimension Capital with participation from Y Combinator to expand its platform for coordinating and deploying AI models in …

Continue ›››

New AI-Native Biotechs: 2026 Watchlist

Just a few days ago, the FDA formally established a one-pivotal-trial default for drug approval, explicitly emphasizing mechanistic, real-world, and model-based “confirmative evidence” around that study. Under the updated framework, …

Continue ›››

Five Genomics Watchpoints for 2026

Industrial functional genomics, modular gene editing, embryo ranking, falling sequencing costs, and scaled DNA synthesis start to connect into one end-to-end pipeline. The beginning of this year is already offering …

Continue ›››

Companies Applying AI to De-Risk Clinical Trials: 2026 Watchlist

Clinical development is still shaped by a stubborn asymmetry: only around one in ten drug candidates that enter human testing ever reaches approval, and Phase II/III failures remain the biggest …

Continue ›››

New-Modality Drugs Behind Today’s Big Headlines

How advanced therapeutics are solving “undruggable” biology and creating industry’s most valuable assets. A lot has been happening lately across biopharma spanning massive deals and landmark approvals. Madrigal Pharmaceuticals has …

Continue ›››

Five Women Shaping the AI–Life Science Stack

February 11 marks the UN-designated International Day of Women and Girls in Science, established by the General Assembly in December 2015 to recognize the contributions of women in scientific fields …

Continue ›››

Big Pharma’s China Deal Wave & 12 Companies on Our Radar

A snap look at some of the deal dynamics and company platforms pulling global pharma toward China. In late January, AstraZeneca announced a $15B investment in China through 2030, expanding …

Continue ›››

How 2026 Started: First-Weeks Readout on AI, Pharma, & Policy

Early-year overview spanning virtual cell modeling, AI workflow plumbing in R&D and healthcare, obesity-driven capital and licensing, patent-cliff positioning, and FDA/EU policy signals. The year opened hot, with the first …

Continue ›››